Actavis Acquires Kadian

Actavis has acquired the brandname drug Kadian from King Pharmaceuticals for not more than $127.5 million. The drug is an extended release morphine sulfate product, and is the first originator brand product to be marketed by Actavis US.

The company anticipates marketing Kadian only in the US.

It is used to treat moderate to severe chronic pain, is a currently marketed in 20mg, 30mg, 50mg, 60mg, 80mg, 100mg and 200mg dosage strength capsules.